STOCK TITAN

[Form 4] NeuroOne Medical Technologies Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filed for NeuroOne Medical Technologies Corp. (NMTC) discloses a minor insider transaction by Chief Technology Officer Steve Mertens on 30 June 2025.

  • Transaction type: Code F, which reflects shares withheld to satisfy tax obligations.
  • Shares affected: 906 common shares at an indicated price of $0.678 per share.
  • Post-transaction holding: Mertens directly owns 162,235 NMTC common shares.
  • Derivative securities: None reported.

The filing represents routine tax-related share withholding and does not indicate open-market buying or selling. The magnitude—<1% of the executive’s reported holdings—is too small to materially affect ownership structure or signal a strategic shift.

Il modulo 4 presentato per NeuroOne Medical Technologies Corp. (NMTC) segnala una piccola operazione interna da parte del Chief Technology Officer Steve Mertens in data 30 giugno 2025.

  • Tipo di transazione: Codice F, che indica azioni trattenute per adempiere agli obblighi fiscali.
  • Azioni coinvolte: 906 azioni ordinarie al prezzo indicato di $0,678 per azione.
  • Detenzione post-transazione: Mertens possiede direttamente 162.235 azioni ordinarie NMTC.
  • Strumenti derivati: Nessuno segnalato.

La comunicazione rappresenta una normale trattenuta di azioni per motivi fiscali e non indica acquisti o vendite sul mercato aperto. L'entità—<1% delle partecipazioni dichiarate dell’esecutivo—è troppo piccola per influenzare significativamente la struttura proprietaria o indicare un cambiamento strategico.

El formulario 4 presentado para NeuroOne Medical Technologies Corp. (NMTC) revela una transacción menor por parte del Director de Tecnología Steve Mertens el 30 de junio de 2025.

  • Tipo de transacción: Código F, que refleja acciones retenidas para cumplir con obligaciones fiscales.
  • Acciones afectadas: 906 acciones comunes a un precio indicado de $0.678 por acción.
  • Participación después de la transacción: Mertens posee directamente 162,235 acciones comunes de NMTC.
  • Valores derivados: No reportados.

La presentación representa una retención rutinaria de acciones por impuestos y no indica compras o ventas en el mercado abierto. La magnitud —<1% de las participaciones reportadas del ejecutivo— es demasiado pequeña para afectar materialmente la estructura de propiedad o señalar un cambio estratégico.

NeuroOne Medical Technologies Corp. (NMTC)에 대한 4호 양식 제출은 최고기술책임자(CTO) Steve Mertens2025년 6월 30일에 소액 내부거래를 신고했음을 나타냅니다.

  • 거래 유형: 코드 F, 세금 의무를 충족하기 위해 주식을 원천징수한 것을 의미합니다.
  • 영향받은 주식: 주당 $0.678의 가격으로 906 보통주.
  • 거래 후 보유 주식: Mertens는 직접 162,235 NMTC 보통주를 보유하고 있습니다.
  • 파생 증권: 보고된 바 없습니다.

이 제출은 세금 관련 주식 원천징수의 일환으로, 공개 시장에서의 매매를 나타내지 않습니다. 규모는—임원 보고 보유량의 <1%—소유 구조에 중대한 영향을 미치거나 전략적 변화를 시사하기에는 너무 작습니다.

Le formulaire 4 déposé pour NeuroOne Medical Technologies Corp. (NMTC) révèle une transaction mineure d’initié par le Directeur Technique Steve Mertens le 30 juin 2025.

  • Type de transaction : Code F, correspondant à des actions retenues pour satisfaire des obligations fiscales.
  • Actions concernées : 906 actions ordinaires au prix indiqué de 0,678 $ par action.
  • Position après transaction : Mertens détient directement 162 235 actions ordinaires NMTC.
  • Instruments dérivés : Aucun signalé.

Le dépôt représente une retenue d’actions de routine liée aux impôts et n’indique pas d’achats ou de ventes sur le marché ouvert. L’ampleur—<1 % des participations déclarées de l’exécutif—est trop faible pour affecter significativement la structure de propriété ou signaler un changement stratégique.

Das für NeuroOne Medical Technologies Corp. (NMTC) eingereichte Formular 4 offenbart eine geringfügige Insider-Transaktion des Chief Technology Officer Steve Mertens am 30. Juni 2025.

  • Transaktionstyp: Code F, der zurückbehaltene Aktien zur Erfüllung steuerlicher Verpflichtungen widerspiegelt.
  • Betroffene Aktien: 906 Stammaktien zum angegebenen Preis von $0,678 pro Aktie.
  • Bestand nach der Transaktion: Mertens besitzt direkt 162.235 NMTC-Stammaktien.
  • Derivative Wertpapiere: Keine gemeldet.

Die Einreichung stellt eine routinemäßige steuerbedingte Aktienrückbehaltung dar und deutet nicht auf Käufe oder Verkäufe am offenen Markt hin. Das Volumen—<1% der gemeldeten Bestände des Geschäftsführers—ist zu gering, um die Eigentümerstruktur wesentlich zu beeinflussen oder auf eine strategische Veränderung hinzuweisen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding of 906 shares; negligible ownership impact, neutral signal.

The Code F classification shows shares were surrendered to cover tax obligations tied to equity compensation rather than an elective sale. Mertens retains over 162 k shares, so insider alignment remains largely unchanged. Given the tiny volume and lack of market transaction, the Form 4 is informational but not valuation-relevant. I rate the market impact neutral.

Il modulo 4 presentato per NeuroOne Medical Technologies Corp. (NMTC) segnala una piccola operazione interna da parte del Chief Technology Officer Steve Mertens in data 30 giugno 2025.

  • Tipo di transazione: Codice F, che indica azioni trattenute per adempiere agli obblighi fiscali.
  • Azioni coinvolte: 906 azioni ordinarie al prezzo indicato di $0,678 per azione.
  • Detenzione post-transazione: Mertens possiede direttamente 162.235 azioni ordinarie NMTC.
  • Strumenti derivati: Nessuno segnalato.

La comunicazione rappresenta una normale trattenuta di azioni per motivi fiscali e non indica acquisti o vendite sul mercato aperto. L'entità—<1% delle partecipazioni dichiarate dell’esecutivo—è troppo piccola per influenzare significativamente la struttura proprietaria o indicare un cambiamento strategico.

El formulario 4 presentado para NeuroOne Medical Technologies Corp. (NMTC) revela una transacción menor por parte del Director de Tecnología Steve Mertens el 30 de junio de 2025.

  • Tipo de transacción: Código F, que refleja acciones retenidas para cumplir con obligaciones fiscales.
  • Acciones afectadas: 906 acciones comunes a un precio indicado de $0.678 por acción.
  • Participación después de la transacción: Mertens posee directamente 162,235 acciones comunes de NMTC.
  • Valores derivados: No reportados.

La presentación representa una retención rutinaria de acciones por impuestos y no indica compras o ventas en el mercado abierto. La magnitud —<1% de las participaciones reportadas del ejecutivo— es demasiado pequeña para afectar materialmente la estructura de propiedad o señalar un cambio estratégico.

NeuroOne Medical Technologies Corp. (NMTC)에 대한 4호 양식 제출은 최고기술책임자(CTO) Steve Mertens2025년 6월 30일에 소액 내부거래를 신고했음을 나타냅니다.

  • 거래 유형: 코드 F, 세금 의무를 충족하기 위해 주식을 원천징수한 것을 의미합니다.
  • 영향받은 주식: 주당 $0.678의 가격으로 906 보통주.
  • 거래 후 보유 주식: Mertens는 직접 162,235 NMTC 보통주를 보유하고 있습니다.
  • 파생 증권: 보고된 바 없습니다.

이 제출은 세금 관련 주식 원천징수의 일환으로, 공개 시장에서의 매매를 나타내지 않습니다. 규모는—임원 보고 보유량의 <1%—소유 구조에 중대한 영향을 미치거나 전략적 변화를 시사하기에는 너무 작습니다.

Le formulaire 4 déposé pour NeuroOne Medical Technologies Corp. (NMTC) révèle une transaction mineure d’initié par le Directeur Technique Steve Mertens le 30 juin 2025.

  • Type de transaction : Code F, correspondant à des actions retenues pour satisfaire des obligations fiscales.
  • Actions concernées : 906 actions ordinaires au prix indiqué de 0,678 $ par action.
  • Position après transaction : Mertens détient directement 162 235 actions ordinaires NMTC.
  • Instruments dérivés : Aucun signalé.

Le dépôt représente une retenue d’actions de routine liée aux impôts et n’indique pas d’achats ou de ventes sur le marché ouvert. L’ampleur—<1 % des participations déclarées de l’exécutif—est trop faible pour affecter significativement la structure de propriété ou signaler un changement stratégique.

Das für NeuroOne Medical Technologies Corp. (NMTC) eingereichte Formular 4 offenbart eine geringfügige Insider-Transaktion des Chief Technology Officer Steve Mertens am 30. Juni 2025.

  • Transaktionstyp: Code F, der zurückbehaltene Aktien zur Erfüllung steuerlicher Verpflichtungen widerspiegelt.
  • Betroffene Aktien: 906 Stammaktien zum angegebenen Preis von $0,678 pro Aktie.
  • Bestand nach der Transaktion: Mertens besitzt direkt 162.235 NMTC-Stammaktien.
  • Derivative Wertpapiere: Keine gemeldet.

Die Einreichung stellt eine routinemäßige steuerbedingte Aktienrückbehaltung dar und deutet nicht auf Käufe oder Verkäufe am offenen Markt hin. Das Volumen—<1% der gemeldeten Bestände des Geschäftsführers—ist zu gering, um die Eigentümerstruktur wesentlich zu beeinflussen oder auf eine strategische Veränderung hinzuweisen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mertens Steve

(Last) (First) (Middle)
7599 ANAGRAM DR.

(Street)
EDEN PRAIRIE MN 55344

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Technology Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 F 906 D $0.678 162,235 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24, Power of Attorney, is attached.
/s/ Emily Johns, by Power of Attorney 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NMTC shares did CTO Steve Mertens dispose of?

The filing shows 906 shares were withheld for taxes (Code F).

What is Steve Mertens’ current NMTC shareholding after the transaction?

He directly owns 162,235 common shares.

Was this an open-market sale of NMTC stock?

No. Code F indicates shares were withheld by the company to cover tax liabilities, not sold on the market.

Were any NMTC derivative securities involved?

No derivative securities were reported in Table II of the Form 4.
Neuroone Med Technologies Corp

NASDAQ:NMTC

NMTC Rankings

NMTC Latest News

NMTC Latest SEC Filings

NMTC Stock Data

36.42M
43.50M
24%
16.68%
0.66%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
EDEN PRAIRIE